Variable name;level;Overall;IVM;At least one COS;p;test
;n;262;172;83;;
Age;[0 -40);258;169 (67.3);82 (32.7);1.000;
;40+;4;3 (75);1 (25);;
Age (mean);;32.7 (3.7);32.4 (3.8);33.4 (3.6);0.055;
Number of children;0;177;117 (68);55 (32);0.929;
;1;53;35 (67.3);17 (32.7);;
;More than 1;32;20 (64.5);11 (35.5);;
BMI;<18.5;16;4 (26.7);11 (73.3);0.006;
;25-29.9;46;34 (73.9);12 (26.1);;
;>=30;12;9 (75);3 (25);;
;18.5-24.9;181;120 (68.6);55 (31.4);;
BMI (mean);;22.0 [20.3, 24.5];22.6 [20.4, 25.1];21.6 [19.9, 24.4];0.080;nonnorm
Treatment center;Curie Paris;168;113 (68.5);52 (31.5);NaN;
;Curie St Cloud;94;59 (65.6);31 (34.4);;
;Others;0;0 (NaN);0 (NaN);;
Genetic Analysis;No;55;33 (61.1);21 (38.9);0.339;
;Yes;207;139 (69.2);62 (30.8);;
Hereditary predisposition;No;159;109 (70.3);46 (29.7);0.509;
;Yes;46;28 (63.6);16 (36.4);;
Inflammatory BC;No;260;170 (67.2);83 (32.8);0.819;
;Yes;2;2 (100);0 (0);;
Clinical Tumor size (mm);;32.0 (20.2);37.0 (21.1);21.8 (13.9);<0.001;
Clinical N stage (TNM);N0;165;98 (61.6);61 (38.4);0.011;
;N1-N2-N3;96;74 (77.9);21 (22.1);;
SBR grade;Grade I-II;107;70 (65.4);37 (34.6);0.677;
;Grade III;154;101 (68.7);46 (31.3);;
Histological type;NST;249;167 (68.7);76 (31.3);0.123;
;Lobular;6;3 (50);3 (50);;
;Others;7;2 (33.3);4 (66.7);;
Neoajuvant chemotherapy;No;118;38 (33);77 (67);<0.001;
;Yes;144;134 (95.7);6 (4.3);;
Chemotherapy setting;NAC;144;134 (95.7);6 (4.3);NaN;
;Adjuvant;118;38 (33);77 (67);;
;NAC and adjuvant;0;0 (NaN);0 (NaN);;
;Chemotherapy without surgery;0;0 (NaN);0 (NaN);;
;No;0;0 (NaN);0 (NaN);;
Fertility preservation discussion;No;3;2 (66.7);1 (33.3);1.000;
;Yes;259;170 (67.5);82 (32.5);;
